Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of oral WJ05129 in advanced solid tumors
CTR20220398Phase 2Terminated
- Sponsor
- Junjing Bio
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WJ05129 in Nonhematologic neoplasms, sponsored by Junjing Bio. Started Sep 2022; status: terminated.
02
Drugs
WJ05129
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20220398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220398.